Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog

By
A A A

Eli Lilly and Company ( LLY ) and partner Boehringer Ingelheim Pharmaceuticals, Inc. announced that the new drug application (NDA) for their empagliflozin−Tradjenta (linagliptin) combination has been accepted for review by the U.S. Food and Drug Administration (FDA). The companies are looking to get the combination approved for the treatment of adults suffering from type II diabetes.

We note that empagliflozin is also under review for type II diabetes in the U.S. and the EU. Recently, empagliflozin received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for this indication. Eli Lilly and its partner intend to launch it in 2014, if approved. Eli Lilly has another candidate, dulaglutide, under review in the U.S. and the EU for this indication.

Eli Lilly is working on strengthening its diabetes franchise. However, the market is highly crowded given the presence of players like Novo Nordisk ( NVO ) and Merck ( MRK ) among others.

Meanwhile, Eli Lilly is facing a major challenge in the form of loss of exclusivity for Zyprexa and Cymbalta. However, the Animal Health business and the diabetes franchise should provide some downside support.

We are also pleased to see Eli Lilly pursuing small acquisitions and in-licensing deals to boost its pipeline.

We expect 2014 to be a catalyst rich year for Eli Lilly with the expected filing of a number of regulatory applications and a few product launches.

Eli Lilly carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is Questcor Pharmaceuticals, Inc. ( QCOR ), carrying a Zacks Rank #1 (Strong Buy).



LILLY ELI & CO (LLY): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: CHMP , LLY , MRK , NVO , QCOR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

100%
100%
0%

Most Active by Volume

61,354,178
  • $10.59 ▲ 13.26%
57,732,182
  • $16.27 ▲ 1.12%
51,991,548
  • $103.30 ▲ 0.78%
48,129,834
  • $20.65 ▲ 5.52%
41,623,916
  • $12.63 ▲ 8.13%
34,295,241
  • $76.68 ▲ 2.49%
31,519,079
  • $34.57 ▼ 1.00%
28,847,879
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com